Pages that link to "Q35140001"

The following pages link to HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial (Q35140001):

Displaying 17 items.

• Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective (Q26770839) (← links)
• Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data (Q26801501) (← links)
• The evolution of poxvirus vaccines (Q26995905) (← links)
• COMPASS identifies T-cell subsets correlated with clinical outcomes (Q27314516) (← links)
• A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults (Q35593139) (← links)
• Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. (Q35798892) (← links)
• Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses (Q35808262) (← links)
• Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates (Q35914311) (← links)
• A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine (Q36003208) (← links)
• Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012) (Q36192765) (← links)
• Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. (Q38675720) (← links)
• New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design. (Q38748193) (← links)
• Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response. (Q40235609) (← links)
• HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci (Q40339467) (← links)
• A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract (Q40844843) (← links)
• Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine. (Q47105096) (← links)
• Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector (Q92288781) (← links)